Mumbai, Feb 14: Metropolis Healthcare Limited, India’s second-largest and one of the most trusted pathology laboratory chains, hosted a high-impact Scientific Symposium on Genomics in Mumbai, convening over 300 clinicians, researchers, scientists, and academicians to advance the clinical integration of genomic diagnostics across India’s healthcare ecosystem.
The symposium marked the formal unveiling of the Metropolis Centre of Genomics to the clinician community, reinforcing the Company’s broader clinical engagement strategy focused on embedding advanced molecular diagnostics into routine medical practice. As precision medicine gains momentum in India and globally, the forum spotlighted the transition from episodic testing to integrated, molecular-driven care pathways enabling earlier diagnosis, precise risk stratification, and personalised treatment across oncology, neurology, and women & child health.
Advancing Precision Medicine Across Specialties
The symposium featured thematic discussions across key clinical domains:
- Oncology: Experts highlighted tumour profiling, biomarker-driven therapies, and the expanding role of next-generation sequencing (NGS) in guiding targeted cancer care.
- Neurogenomics: Sessions focused on inherited and rare neurological disorders, including genetic epilepsies and neuromuscular conditions, demonstrating how genomic insights can reduce diagnostic delays and enable personalised management.
- Women & Child Health: Deliberations explored reproductive genomics, prenatal diagnostics, and genetic counselling, underscoring the importance of early molecular insights in improving pregnancy and paediatric outcomes.
Parallel sub-specialty sessions led by Key Opinion Leaders, Medical Advisory Board members, and distinguished national and international speakers featured panel discussions and case-based deliberations to deepen clinical engagement.
Clinicians also shared real-world case experiences illustrating how genomics is enabling a shift from symptomatic management to evidence-based, targeted interventions—enhancing diagnostic clarity and reducing uncertainty in complex cases.
Leadership Commentary
Commenting on the initiative, Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited, said:
“The next phase of healthcare will be defined by how effectively genomic intelligence is embedded into clinical workflows at scale. The opportunity ahead lies in creating connected ecosystems where diagnostics, data science, and clinical expertise work seamlessly together. At Metropolis, we are focused on integrating molecular intelligence into everyday decision-making so that precision medicine moves toward becoming the standard of care, not the exception.”
Dr. Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Ltd., added:
“As genomic medicine expands, the real challenge is not access to technology but ensuring accuracy, interpretation, and accountability at every step. Scaling responsibly requires rigorous validation frameworks, structured reporting standards, and close collaboration between scientists and clinicians so that genomic findings are applied with clarity and confidence in patient care.”
Eminent Participation
The symposium witnessed participation from an eminent panel of national and international clinicians and experts, including:
- Suresh Advani, Senior Consultant, Medical Oncology, Jaslok Hospital
- Aniruddha Deshpande, Professor, Sanford Burnham Prebys, California
- Stefan Bohlander, Department of Molecular Medicine, University of Auckland
- Jyoti Bajpai, Senior Consultant, Precision Oncology
- Sunita Tandulwadkar, Ex-President, FOGSI
- Anupkumar Rawool, Founder & Director, Sahaj Genetic Clinic
Among several other distinguished oncologists, neurologists, paediatric specialists, geneticists, and fetal medicine experts from leading institutions across India.